PharVision Advisers’s Danaher DHR Stock Holding History

PharVision Advisers’s Portfolio DHR Stock Details DHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,384	Closed	-$284K	–	305
2025 Q1	$284K	Buy	+1,384	New	+$302K	0.39%	101

Other funds holding DHR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

PharVision Advisers's DHR Position: Q2 2025 in Review

PharVision Advisers sold out of Danaher (DHR) in Q2 2025, closing a stake of 1,384 shares — an estimated $284K sold.

PharVision Advisers first reported a position in DHR in Q1 2025 and held it in 1 quarter. The position peaked at $284K in Q1 2025. 2,171 funds tracked by Wall St. Rank hold DHR as of Q2 2025.

PharVision Advisers reported no remaining Danaher position as of Q2 2025 after selling out during the quarter.
PharVision Advisers sold 1,384 Danaher shares in Q2 2025, an estimated $284K.
PharVision Advisers first reported a position in Danaher in Q1 2025 and held it in 1 quarter.
PharVision Advisers's Danaher position peaked at $284K in Q1 2025.
2,171 funds tracked by Wall St. Rank held Danaher as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.